Skip to main content
. Author manuscript; available in PMC: 2013 Jun 14.
Published in final edited form as: Cardiovasc Res. 2012 Jan 31;94(1):30–37. doi: 10.1093/cvr/cvs076

Figure 2. Immunoregulatory effects of the CD31 peptide in vivo.

Figure 2

a. The percentage of Tregs (CD25+ FoxP3+) was increased while the relative fraction of activated T-cells (CD69+) CD4+ T-cells among total blood CD3+ T-cells was diminished by the peptide treatment (*p<0.05). b. Plasma IL-2, IFNγ, IL-4 and IL-6 (a.u.) were significantly decreased by the peptide treatment in vivo (*p<0.05).